

The Quantitative Imaging Biomarkers Alliance (*QIBA*) was organized by RSNA in 2007 to unite researchers, healthcare professionals, and industry stakeholders in the advancement of quantitative imaging and the use of biomarkers in clinical trials and practice.

Definition

Quantitative imaging is the acquisition, extraction and characterization of relevant quantifiable features from medical images for use in research and patient care. Standardizing the use of imaging biomarkers in clinical trials will reduce the variance inherent across different hardware and software platforms. RSNA views this work as a step toward an ultimate goal of enhancing the use of quantitative imaging methods in clinical practice.

QIBA is an important part of RSNA's commitment to transforming radiology from a *qualitative* to a more *quantitative* science and to the improved patient care resulting from accelerated development and dissemination of new pharmacologic, biologic and interventional diagnosis and treatment approaches.

QIBA Mission

Improve the value and practicality of quantitative imaging biomarkers by reducing variability across devices, patients and time.

The work of QIBA has advanced through the generous efforts of volunteer members from academia, the medical device industry, the pharmaceutical and other business sectors, and government. There are 13 biomarker committees open to all interested persons. These Committees have specific tasks and deliverables for their respective modalities and disease-based approach:

CT Volumetry Lung Density Functional magnetic resonance imaging (fMRI) Magnetic resonance elastography (MRE) Musculoskeletal (MSK) Perfusion, Diffusion and Flow MRI (PDF-MRI) Proton Density Fat Fraction (PDFF) FDG-PET/CT PET-Amyloid Single-photon emission computed tomography (SPECT) Ultrasound Shear Wave Speed (US-SWS) Ultrasound Volume Blood Flow (US-VBF) [AIUM] Contrast Enhanced Ultrasound (CEUS)

The QIBA Approach

The work of the QIBA Committees follows a defined, coordinated process to develop solutions and promote their adoption.

I. *Identify Sources of Error and Variation in Quantitative Results from Imaging Methods:* Stakeholders work to identify problems leading to error or variability in quantitative results from imaging methods.

II. *Specify Potential Solutions:* Stakeholders identify potential strategies and infrastructure for error mitigation and collaborate on development of hardware, software, and protocol solutions, documenting them in the form of QIBA Profiles.

III. Test Solutions: Vendors and researchers implement QIBA solutions to assess their feasibility and efficacy.

IV. *Promulgate Solutions:* Validated solutions are disseminated and implemented through vendor adoption, research integration and clinical education.

QIBA Resources

QIBA meeting summaries, key criteria for identifying biomarker opportunities, the *QIBA Newsletter* and other documents are available on the QIBA website <u>RSNA.ORG/QIBA</u> and wiki <u>http://qibawiki.rsna.org/</u>

Volunteers for the QIBA Committees are welcome; please contact us at: qiba@rsna.org QIBA Committees

QIBA Governance Structure

QIBA Chair: QIBA Vice Chair:	Edward F. Jackson, PhD Alex Guimaraes, MD, PhD	(University of Wisconsin, School of Medicine & Public Health) (Oregon Health & Science University)
Scientific Liaison: CT:	Andrew J. Buckler, MS	(Elucid Bioimaging, Inc.)
Scientific Liaison: MR:	Thomas L. Chenevert, PhD	(University of Michigan Health System)
Scientific Liaison: NM:	Paul E. Kinahan, PhD	(University of Washington)
Scientific Liaison: US:	Paul L. Carson, PhD	(University of Michigan Health System)

Process Committee

Chair:	Kevin O'Donnell, MASc	(Toshiba Medical Research Institute USA, Inc.)
Vice Chair:	Daniel Sullivan, MD	(Duke University Medical Center)

Coordinating Committees

Computed Tomography (CT) Coordinating Committee

Co-Chairs:	Rudresh Jarecha, MBBS, DNB, DMRE	(PAREXEL International)
	Lawrence Schwartz, MD	(New York Presbyterian Hospital / Columbia University)
Vice Chair:	David Lynch, MD	(National Jewish Health)

Magnetic Resonance Imaging (MR) Coordinating Committee

Co-Chairs:	Mark Rosen, MD, PhD	(University of Pennsylvania)
	Gudrun Zahlmann, PhD	(F. Hoffmann-La Roche Ltd.)
Vice Chair:	Cathy Elsinger, PhD	(NordicNeuroLab, Inc.)

Nuclear Medicine (NM) Coordinating Committee

Co-Chairs:	Richard Wahl, MD	(Mallinckrodt Institute, Washington University)
	Eric Perlman, MD	(Perlman Advisory Group, LLC)
Vice Chair:	P. David Mozley, MD	(Weill Cornell Medical College)

Ultrasound (US) Coordinating Committee

Chair:	Tim Hall, PhD	(University of Wisconsin, School of Medicine & Public Health)
Vice Chair:	Brian Garra, MD	(Washington DC VA Medical Center / FDA)

Biomarker Committees (by imaging modality)

CT Volumetry

Co-Chairs:Gregory V. Goldmacher, MD, PhD, MBA(Merck)Ehsan Samei, PhD(Duke University Medical Center)Jenifer Siegelman, MD, MPH(Takeda Pharmaceuticals)

Lung Density

Chair:	
Sean Fain, PhD	(University of Wisconsin, School of Medicine & Public Health)
Matthew Fuld, PhD	(Siemens Medical Solutions USA, Inc.)
David Lynch, MD	(National Jewish Health)

(Medical College of Wisconsin) (Johns Hopkins University)

(Cole Imaging and Biomarker Consulting, LLC)

(Prism Clinical Imaging, Inc.)

(Mayo Clinic)

fMRI

Co-Chairs: Edgar DeYoe, PhD Jay Pillai, MD James Reuss, PhD

MRE

Co-Chairs: Patricia Cole, PhD, MD Richard Ehman, MD

MSK

Co-Chairs Thomas Link, MD, PhD Xiaojuan Li, PhD

Perfusion, Diffusion and Flow - MRI Co-Chairs:

Michael Boss, PhD John Kirsch, PhD Daniel Barboriak, MD

(NIST) (Massachusetts General Hospital) (Duke University)

(University of California, San Francisco)

(Cleveland Clinic Foundation)

Proton Density Fat Fraction

Co-Chairs: Scott Reeder, MD, PhD Takeshi Yokoo, MD, PhD

(University of Wisconsin, School of Medicine & Public Health) (University of Texas Southwestern Medical Center)

FDG-PET

Co-Chairs: Rathan Subramaniam, MD, PhD, MPH John J. Sunderland, PhD Scott Wollenweber, PhD

PET-Amyloid

Co-chairs:

Satoshi Minoshima, MD, PhD Anne Smith, PhD

SPECT

Co-Chairs: Yuni Dewaraja, PhD P. David Mozley, MD (University of Texas, Southwestern Medical Center) (University of Iowa) (GE Healthcare)

(University of Utah) (Siemens Medical Solutions USA, Inc.)

(University of Michigan Health System) (Weill Cornell Medical College)

Contrast Enhanced Ultrasound (Cl	EUS)
----------------------------------	------

Co-Chairs:	
Michalakis (Mike) A. Averkiou, PhD	(University of Washington, Seattle)
Richard G. Barr, MD, PhD	(Northeastern Ohio Medical University)
Ultrasound Shear Wave Speed Co-Chairs:	

(Washington DC VA Medical Center / FDA) Brian Garra, MD (University of Wisconsin, School of Medicine & Public Health) Timothy J. Hall, PhD Andy Milkowski, MS (Siemens Medical Solutions USA, Inc.) Ultrasound Volume Blood Flow [Supported by AIUM]

Co-Chairs:

J. Brian Fowlkes, PhD	(University of Michigan Health System)
Oliver Kripfgans, PhD	(University of Michigan Health System)

Updated 21-Aug-2017